-$0.99 EPS Expected for Ascendis Pharma A/S (ASND) This Quarter

Equities analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to announce earnings per share (EPS) of ($0.99) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Ascendis Pharma A/S’s earnings, with estimates ranging from ($1.10) to ($0.72). Ascendis Pharma A/S posted earnings per share of ($1.04) in the same quarter last year, which indicates a positive year over year growth rate of 4.8%. The firm is expected to issue its next earnings results on Friday, August 17th.

According to Zacks, analysts expect that Ascendis Pharma A/S will report full year earnings of ($4.22) per share for the current financial year, with EPS estimates ranging from ($4.71) to ($3.44). For the next fiscal year, analysts forecast that the company will post earnings of ($3.24) per share, with EPS estimates ranging from ($5.46) to $1.15. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, March 28th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.16). The business had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.58 million. Ascendis Pharma A/S had a negative return on equity of 64.87% and a negative net margin of 12,089.94%.

Several brokerages have recently weighed in on ASND. Leerink Swann reiterated a “market perform” rating and set a $70.00 price target (up previously from $64.00) on shares of Ascendis Pharma A/S in a research note on Thursday, May 31st. Wedbush reiterated an “outperform” rating and set a $76.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, May 15th. BidaskClub cut shares of Ascendis Pharma A/S from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 7th. Zacks Investment Research upgraded shares of Ascendis Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 21st. Finally, ValuEngine upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Ascendis Pharma A/S currently has an average rating of “Buy” and an average price target of $68.33.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Atria Investments LLC purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $212,000. Quantbot Technologies LP purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $215,000. Kovack Advisors Inc. purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $218,000. Jane Street Group LLC purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $250,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $255,000. Institutional investors own 91.82% of the company’s stock.

Shares of Ascendis Pharma A/S stock opened at $68.90 on Monday. The firm has a market cap of $2.88 billion, a PE ratio of -15.89 and a beta of 0.69. Ascendis Pharma A/S has a 1-year low of $21.95 and a 1-year high of $76.29.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit